Bcg (Bcg (Bacillus Calmette-Guérin) Bacteria)

Bcg is indicated for intravesical immunotherapy of non‑muscle invasive bladder cancer, typically after transurethral tumor resection. It is employed to reduce the risk of tumor recurrence and progression.

• Administered directly into the bladder via catheter.
• Used in patients with high‑risk or intermediate‑risk disease.
• Applied following complete endoscopic tumor removal.
• Considered when bladder‑preserving therapy is desired.
• May be part of clinical trial protocols for urothelial malignancies.

Bcg can cause a range of local and systemic reactions. Most patients experience mild to moderate symptoms that resolve without intervention, while rare serious events may require medical attention.

Common

• Cystitis‑like symptoms such as urinary urgency and frequency.
• Mild hematuria or blood in urine.
• Low‑grade fever and chills.
• Fatigue or general malaise.
• Mild abdominal discomfort.
• Local bladder irritation.

Serious

• Systemic BCG infection (BCGitis) with fever and sepsis.
• Severe allergic reactions including anaphylaxis.
• Persistent hematuria requiring intervention.
• Bladder contracture or fibrosis.
• Disseminated mycobacterial infection.
• Organ‑specific granulomatous inflammation.

Bcg should be used with caution in specific patient populations and clinical situations to minimize the risk of adverse outcomes.

• Contraindicated in patients with active tuberculosis or known hypersensitivity to mycobacterial products.
• Not recommended for immunocompromised individuals, including those on high‑dose steroids or chemotherapy.
• Use with caution in patients with recent bladder instrumentation or trauma.
• Pregnancy and lactation status should be evaluated, as safety data are limited.
• Evaluate renal function before administration, especially in patients with chronic kidney disease.
• Monitor for signs of systemic infection after each treatment.

Bcg may interact with other therapies that affect immune function or bladder integrity. Certain agents should be avoided, while others require careful monitoring.

Avoid

• Concurrent use of systemic immunosuppressants (e.g., azathioprine, cyclosporine).
• Live vaccines administered within four weeks before or after Bcg therapy.
• Systemic antibiotics that may reduce Bcg viability when given shortly before treatment.

Use with caution

• Intravesical chemotherapy agents administered close to Bcg dosing.
• Anticoagulants or antiplatelet drugs due to increased bleeding risk.
• Systemic corticosteroids, which may diminish therapeutic effect.
• Radiation therapy to the pelvis, which may exacerbate bladder irritation.